| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q53890584 | 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. |
| Q81021550 | 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial |
| Q33390454 | A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer |
| Q41656689 | A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer |
| Q36883091 | A causal role for ERG in neoplastic transformation of prostate epithelium. |
| Q73679998 | A challenge for the diagnostic immunohistopathologist. Adding the CD phenotypes to our diagnostic toolbox |
| Q114109163 | A hybrid open-top light-sheet microscope for versatile multi-scale imaging of cleared tissues |
| Q38066715 | A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray |
| Q34984241 | A molecular correlate to the Gleason grading system for prostate adenocarcinoma |
| Q40978920 | A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer |
| Q35747677 | A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49 |
| Q35178389 | Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors |
| Q57693275 | Active surveillance for prostate cancer: the role of the pathologist |
| Q33693256 | Aggressive variants of castration-resistant prostate cancer |
| Q32123158 | An expressed-sequence-tag database of the human prostate: sequence analysis of 1168 cDNA clones. |
| Q42474443 | Analysis and sorting of prostate cancer cell types by flow cytometry |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q81748580 | Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence |
| Q47670505 | Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling |
| Q37305014 | Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer |
| Q58598144 | Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer |
| Q21558502 | Androgen receptor variants occur frequently in castration resistant prostate cancer metastases |
| Q24813698 | Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression |
| Q45988129 | Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. |
| Q92488758 | Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy |
| Q37085875 | Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. |
| Q41771188 | Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. |
| Q44410099 | Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results |
| Q35738808 | Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment |
| Q49787389 | Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer |
| Q33609625 | CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker |
| Q44303172 | Cathepsin K mRNA and protein expression in prostate cancer progression |
| Q71574504 | Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration |
| Q36592661 | Cell-cell interaction in prostate gene regulation and cytodifferentiation |
| Q41604310 | Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations |
| Q40936806 | Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. |
| Q30596578 | Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases |
| Q30795292 | Characterization of prostate cell types by CD cell surface molecules |
| Q39909790 | Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer |
| Q28542841 | Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes |
| Q57107738 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study |
| Q79149068 | Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy |
| Q89257796 | Comparative Effectiveness of a Patient Centered Pathology Report for Bladder Cancer Care |
| Q37408608 | Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer |
| Q38260303 | Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist |
| Q91288790 | Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer |
| Q33337481 | Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate |
| Q100428109 | De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc |
| Q46249379 | Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine |
| Q36562145 | Development of the Minimum Information Specification for In Situ Hybridization and Immunohistochemistry Experiments (MISFISHIE). |
| Q104482128 | Diagnosing 12 prostate needle cores within an hour of biopsy via open-top light-sheet microscopy |
| Q42861729 | Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices |
| Q39556027 | Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells. |
| Q33276668 | Differential expression of CD10 in prostate cancer and its clinical implication |
| Q38296878 | Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases |
| Q42485853 | Differential expression of osteonectin/SPARC during human prostate cancer progression |
| Q33714055 | Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect |
| Q42049451 | ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. |
| Q57180413 | Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer |
| Q30532494 | Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series |
| Q30724105 | Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases |
| Q35690915 | Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. |
| Q44569597 | Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients |
| Q31137208 | Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia |
| Q43515335 | Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer |
| Q53957275 | Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling. |
| Q33500845 | Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes |
| Q33519740 | Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes |
| Q92538775 | Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features |
| Q92258312 | Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations |
| Q92716286 | Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer |
| Q30485251 | Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients |
| Q120116095 | Harnessing non-destructive 3D pathology |
| Q38783054 | Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile |
| Q38340682 | Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma |
| Q39382172 | Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort |
| Q34618362 | Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. |
| Q35713354 | Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases |
| Q41477497 | Histopathological assessment of prostate cancer bone osteoblastic metastases |
| Q81471856 | How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder? |
| Q24673022 | Human cancers express a mutator phenotype |
| Q81422392 | I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial |
| Q77767053 | I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial |
| Q91734150 | Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer |
| Q38348367 | Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer |
| Q35789925 | Immunohistochemical validation of expression microarray results |
| Q35014686 | Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability |
| Q53788627 | Integrative Clinical Genomics of Advanced Prostate Cancer. |
| Q27853170 | Integrative clinical genomics of advanced prostate cancer |
| Q27313709 | Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study |
| Q112586952 | Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling |
| Q37787737 | International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling |
| Q63966303 | Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists |
| Q80352321 | Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer |
| Q41438400 | Is partial cystectomy the treatment of choice for mucinous adenocarcinoma of the urachus? |
| Q44541707 | Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium |
| Q88638786 | Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens |
| Q34106261 | Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy |
| Q80496193 | Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features |
| Q44304221 | Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase |
| Q79826862 | Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension |
| Q42845103 | Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort |
| Q30843770 | Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma |
| Q52832790 | LuCaP 35: A new model of prostate cancer progression to androgen independence |
| Q42315779 | LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. |
| Q36192598 | MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study |
| Q36876865 | Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth |
| Q80878210 | Metastases of prostate cancer express estrogen receptor-beta |
| Q50077726 | Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review |
| Q43010807 | Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity |
| Q28652074 | Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE) |
| Q38377884 | Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate |
| Q51789451 | Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. |
| Q46972239 | Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. |
| Q30831016 | Molecular and cellular characterization of ABCG2 in the prostate |
| Q28183915 | Molecular characterization of prostatic small-cell neuroendocrine carcinoma |
| Q92285837 | Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer |
| Q51694161 | Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. |
| Q91621957 | Multi-immersion open-top light-sheet microscope for high-throughput imaging of cleared tissues |
| Q112292686 | Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer |
| Q30494070 | Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease |
| Q92496734 | Open-Top Light-Sheet Microscopy Image Atlas of Prostate Core Needle Biopsies |
| Q81296284 | Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma |
| Q42502915 | Osteoprotegerin and rank ligand expression in prostate cancer |
| Q27308897 | Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort |
| Q94519065 | Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer |
| Q37109463 | Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer |
| Q39401816 | PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer |
| Q40116896 | Pathology Imagebase-a reference image database for standardization of pathology. |
| Q34553305 | Persistent intraprostatic androgen concentrations after medical castration in healthy men. |
| Q47744334 | Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone |
| Q73969504 | Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression |
| Q33990394 | Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality |
| Q99571565 | Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey |
| Q58327425 | Prise en charge de la pièce de prostatectomie radicale. Résultats de la conférence de consensus de la Société internationale d’uropathologie (ISUP) |
| Q40772764 | Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies |
| Q36800218 | Prostate cancer cell phenotypes based on AGR2 and CD10 expression |
| Q40574917 | Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence |
| Q33430210 | Prostate cancer-associated gene expression alterations determined from needle biopsies |
| Q33873888 | Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. |
| Q46777281 | Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy |
| Q30563725 | Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma |
| Q37286948 | Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis |
| Q38213296 | Readability of urologic pathology reports: the need for patient-centered approaches. |
| Q102074940 | Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer |
| Q35084939 | Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate |
| Q47359258 | Renal Cell Carcinoma with Angioleiomyoma-Like Stroma and Clear Cell Papillary Renal Cell Carcinoma: Exploring SDHB Protein Immunohistochemistry and the Relationship to Tuberous Sclerosis Complex |
| Q42465071 | Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity |
| Q101451487 | Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program |
| Q42188512 | SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer |
| Q90092692 | Solid immersion meniscus lens (SIMlens) for open-top light-sheet microscopy |
| Q93081058 | Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms |
| Q97557647 | Sporadic Oncocytic Tumors with Features Intermediate between Oncocytoma and Chromophobe Renal Cell Carcinoma: Comprehensive Clinico-Pathological and Genomic Profiling |
| Q25257482 | Stromal mesenchyme cell genes of the human prostate and bladder |
| Q37302524 | Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer |
| Q38242444 | Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports |
| Q50438849 | TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis |
| Q30563985 | Targeted androgen pathway suppression in localized prostate cancer: a pilot study |
| Q80879214 | Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence |
| Q92380638 | Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion |
| Q96690654 | The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer |
| Q42702895 | The accumulation of versican in the nodules of benign prostatic hyperplasia |
| Q35224818 | The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. |
| Q38237017 | The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, Internationa |
| Q92965653 | The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study |
| Q44523441 | The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials |
| Q34087187 | The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells |
| Q29547648 | The landscape of somatic copy-number alteration across human cancers |
| Q37890605 | The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study |
| Q35941464 | The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy |
| Q37036824 | The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy |
| Q37019877 | The role of tissue microarrays in prostate cancer biomarker discovery |
| Q81399958 | The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure |
| Q33309753 | The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder |
| Q33241082 | Transcriptomes of human prostate cells |
| Q34292287 | Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. |
| Q41561012 | Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. |
| Q34109373 | Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner |
| Q30572057 | Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases |
| Q71601596 | Urinary prostate specific antigen levels after radical prostatectomy |
| Q47649299 | Utility of Pathology Imagebase for Standardization of Prostate Cancer Grading |
| Q33658285 | Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention |
| Q33322266 | WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence |
Search more.